西亚试剂优势供应上万种化学试剂产品,欢迎各位新老客户咨询、选购!

登录

¥0.00

联系方式:400-990-3999 / 邮箱:sales@xiyashiji.com

西亚试剂 —— 品质可靠,值得信赖

西亚试剂:Uroporphyrinogen Decarboxylase Is a Radiosensitizing Target

Uroporphyrinogen Decarboxylase Is a Radiosensitizing Target for Head and Neck Cancer

Emma Ito1,2, Shijun Yue2, Eduardo H. Moriyama2, Angela B. Hui2, Inki Kim2, Wei Shi2, Nehad M. Alajez2, Nirmal Bhogal2, GuoHua Li3, Alessandro Datti4,5, Aaron D. Schimmer1,2, Brian C. Wilson1,2, Peter P. Liu3, Daniel Durocher4, Benjamin G. Neel1,2, Brian O’Sullivan6,7, Bernard Cummings6,7, Rob Bristow1,2,6,7, Jeff Wrana4 and Fei-Fei Liu1,2,6,7,*

Head and neck cancer (HNC) is the eighth most common malignancy worldwide, comprising a diverse group of cancers affecting the head and neck region. Despite advances in therapeutic options over the last few decades, treatment toxicities and overall clinical outcomes have remained disappointing, thereby underscoring a need to develop novel therapeutic approaches in HNC treatment. Uroporphyrinogen decarboxylase (UROD), a key regulator of heme biosynthesis, was identified from an RNA interference–based high-throughput screen as a tumor-selective radiosensitizing target for HNC. UROD knockdown plus radiation induced caspase-mediated apoptosis and cell cycle arrest in HNC cells in vitro and suppressed the in vivo tumor-forming capacity of HNC cells, as well as delayed the growth of established tumor xenografts in mice. This radiosensitization appeared to be mediated by alterations in iron homeostasis and increased production of reactive oxygen species, resulting in enhanced tumor oxidative stress. Moreover, UROD was significantly overexpressed in HNC patient biopsies. Lower preradiation UROD mRNA expression correlated with improved disease-free survival, suggesting that UROD could potentially be used to predict radiation response. UROD down-regulation also radiosensitized several different models of human cancer, as well as sensitized tumors to chemotherapeutic agents, including 5-fluorouracil, cisplatin, and paclitaxel. Thus, our study has revealed UROD as a potent tumor-selective sensitizer for both radiation and chemotherapy, with potential relevance to many human malignancies.